目的:研究布病患者血浆microRNA-122(miR-122)和microRNA-146a(miR-146a)作为布病新型诊断标记的可行性.方法:采用实时定量PCR方法,测定验证样本(56例未经治疗的布病患者、32例经过治疗的布病患者和40例健康志愿者)血浆中microRNAs的表达水平.结果:miR-122和miR-146a在布病患者和健康志愿者之间的表达水平差异有统计学意义(P<0.001),并且表达水平与布病患者血清抗体有关,但与患者是否经过抗生素治疗以及患者是否具有明显临床表现均无相关性.miR-122和miR-146a组合诊断的AUC值为0.935,高于两者任何一个单独检测.结论:miR-122和miR-146a组合在布病诊断中具有潜在应用价值.

Objective To identify the potential biomarkers by analyzing microarray dataset of clear cell renal cell carcinoma(ccRCC) and para-carcinoma tissue.Methods ccRCC microarray (GSE6344) was downloaded from Gene Expression Omnibus (GEO).The original data was preprocessed and differentially expressed genes(DEGs)were identified by R language package.The DEGs were analyzed by DAVID,KEGG analysis was performed by clusterProfiler of R language.DEGs-associated protein-protein interaction (PPI) network was analyzed using STRING online software,and Cytoscape was used to filter the hub genes according to the node degree.Results A total of 229 DEGs including 117 up-regulated genes and 112 down-regulated genes were identified from ccRCC GSE dataset.GO analysis results showed that DEGs were mainly enriched in intracellular signaling cascade,ion transport,response to wounding,vasculaturedevelopment,regulation of cell migration and other biological processes.KEGG analysis showed that DEGs were enriched in signaling pathways such as Rap1,MAPK,HIF-1 and so on.Hub genes filtered from PPI network including EGFR,FLT1,ERBB4,EDN1 and ALDOA.Conclusion Bioinformatical analysis of DEGs could improve our understanding of the cause and underlying molecular events,and these hub genes could be diagnostic markers and therapeutic targets for ccRCC.

Objective:To evaluate the effectiveness and safety of most common used regimens against brucellosis.Methods: Search PubMed and CENTRAL database of Cochrane library for all literatures written in English about treatment of brucellosis and CBM database for all RCTs for Brucellosis in Chinese from the year 1985 till now.Assess the quality of the included literatures using Cochrane Collaboration Risk of Bias form.Combine data of relapse,total therapeutic failure,and adverse reaction of regimens for treating human brucellosis.Results: 17 literatures were included.Combined antibiotic therapeutic regimens such as DR,DS,QR and DG were compared.Rate of total therapeutic failure(RRcb:2.53,95%CI:1.51-4.23) and relapse(RRcb:2.69,95%CI:1.46-4.98) of DS regimen was lower than those of DR regimen,while adverse reaction did not show any significant differences between them(RRcb:1.40,95%CI:0.97-2.01).No significant differences were seen in rate of relapse(RRcb:1.24,95%CI:0.67-2.30) and total therapeutic failure(RRcb:1.41,95%CI:0.86-2.32) between QR and DR regimen.QR regimen had lower rate of adverse reaction than DR regimen(RRcb:1.79,95%CI:1.17-2.74).Conclusion: DS regimen priors to DR regimen.QR equals DR in treatment outcome,has fewer adverse reactions meanwhile.Triple antimicrobial based on double regimens seemed to provide better outcomes without a significant increase in adverse reaction,but more clinical evidences are still needed.

目的 探讨CpG ODN1826为佐剂的布氏菌DNA疫苗对C57/BL6小鼠的免疫效果.方法 将C57/BL6小鼠随机分为3组:重组质粒(pcDNA3.1-L7/L12)+CpG ODN1826组(Vaccine+ CpG组,每只注射20μg重组质粒和10 μg CpG ODN1826)、重组质粒组(Vaccine组,每只注射20 μg重组质粒)和对照组(注射生理盐水),注射部位均为后腿胫骨前肌.各组均于初次免疫后2周加强免疫1次.于加强免疫后2周,采用ELISA法检测各组小鼠血清中细胞因子水平;MTT掺入法检测小鼠脾细胞非特异性增殖效应;HE染色观察小鼠脾脏组织学变化.结果 与Vaccine 组和对照组相比,Vaccine+ CpG组小鼠血清中Th1型细胞因子IL-2、IL-12、IFNγ含量均显著升高(P均＜0.01);脾细胞增殖效应明显增强(P＜0.05);脾脏生发中心明显变大,细胞增殖更活跃.结论 CpG ODN1826为佐剂的布氏菌DNA疫苗能够明显诱导C57/BL6小鼠产生Th1型为主的免疫应答,增强脾脏淋巴细胞的增殖反应.